In The Spotlight
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the EC has approved Rixathon® (biosimilar rituximab*) for use in Europe**. Rixathon is approved for use in all indications of the reference medicine, MabThera® ,.
Bristol-Myers Squibb Company announced data from a Phase 2 study of BMS-986036, an investigational pegylated analogue of human fibroblast growth factor 21 (FGF21), a key regulator of metabolism, in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) (F1-F3).
The Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MI) and SOTIO a.s. have signed a collaboration and license agreement providing SOTIO with exclusive rights to an oncology program addressing a novel target in tumor metabolism.
goBalto, Inc., the leading provider of cloud-based clinical study startup (SSU) solutions, announced its partnership with Citeline, part of Informa's Pharma Intelligence vertical, to integrate data from Citeline's intelligence platforms — including Trialtrove and Sitetrove — with goBalto's Select.
Astellas Pharma Inc and Pfizer Inc announced the amendment of the protocol for the registrational PROSPER trial, a multi-national, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of XTANDI in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC).
Selvita , a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML).
Johnson Matthey, a global specialty chemicals company and provider of advanced process technologies, and Rennovia Inc., a privately held company that develops novel catalysts and processes for the cost advantaged production of chemical products from renewable feedstocks.
Mundipharma and Helsinn Group have expanded their collaboration, signing amendments to licensing and distribution agreements for anti-emetic prophylactic agents ALOXI® and AKYNZEO® to cover a host of additional markets.
AMAG Pharmaceuticals, Inc. and Endoceutics, Inc. announced that they have entered into an exclusive license agreement that provides AMAG with U.S. commercial rights to Intrarosa™ (prasterone).
Manufacturers with high volume and high speed production lines rely on their coding and marking system’s availability to keep production lines running.
Sharp Clinical Services (Sharp), part of UDG Healthcare plc , has announced a £9 million investment to fund a new multiple-phase pharmaceutical manufacturing, packaging and distribution facility in Wales.
The initial investment in two state-of-the-art printing presses will primarily serve the healthcare markets in the UK, Switzerland and Germany.